المؤلفون: Hans Petter Eikesdal, Marianne Ewertz, Sajitha Rajendiran, Lars Ottestad, Line Fronth, Liv Hege Aksnes, Egil S. Blix

المصدر: Ottestad, L, Fronth, L, Rajendiran, S, Hege Aksnes, L, Eikesdal, H P, Støre Blix, E & Ewertz, M 2019, ' Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer ', Acta Oncologica, vol. 58, no. 3, pp. 385-387 . https://doi.org/10.1080/0284186X.2019.1566771

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Receptors, Progesterone/metabolism, Receptor, ErbB-2, Receptor, ErbB-2/metabolism, Breast Neoplasms, chemistry.chemical_compound, Exemestane, Breast Neoplasms/drug therapy, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Radiology, Nuclear Medicine and imaging, Androstadienes/administration & dosage, Phosphatidylinositol, Everolimus/administration & dosage, Everolimus, Receptor, Survival rate, PI3K/AKT/mTOR pathway, Aged, Aged, 80 and over, business.industry, Cancer, Hematology, General Medicine, Middle Aged, medicine.disease, Prognosis, Androstadienes, Postmenopause, Survival Rate, chemistry, Receptors, Estrogen, Hormone receptor, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Receptors, Estrogen/metabolism, business, Receptors, Progesterone, medicine.drug, Follow-Up Studies

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38fd880506ec3213ff609b45eaf861ad
https://pubmed.ncbi.nlm.nih.gov/30798641